In-principle approval for Merger of the US-based step-down subsidiary(ies) of the Company

July 29, 2026 BSE Limited National Stock Exchange of India Limited Corporate Service Department, Exchange Plaza, Bandra Kurla Complex, 1st Floor, P. J. Towers, Bandra (E), Dalal Street, Mumbai 400 051 Mumbai 400 001 Scrip Code: 504067 Symbol: ZENSARTECH Sub.: Disclosure pursuant to Regulation 30(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) Dear Sir, Pursuant to Regulation 30 of the SEBI Listing Regulations, we wish to inform you that the Board of Directors of the Company at its meeting held on July 29, 2026, has accorded in-principle approval for Merger of the following US-based step-down subsidiary(ies) of the Company (‘Merging Entities’) into Zensar Technologies Inc., USA, a material wholly owned subsidiary of the Company, either directly or indirectly (by setting up a new entity to enable the merger): i. Bridgeview Life Sciences LLC ii. M3BI LLC The Board/Shareholders of the respective Merging Entities as well as Zensar Technologies Inc., USA will be considering the proposal for the merger separately. Consequent to the Merger, the Merging Entities would cease to exist as step-down subsidiaries of the Company. The details as required under Regulation 30 of the SEBI Listing Regulations read with the SEBI Master Circular dated January 30, 2026, as amended from time to time, in respect to merger of entities are enclosed herewith and marked as Annexure-I. The Board meeting commenced at 05:00 PM (IST) and concluded at 08:05 PM (IST) This is for your information and records. Thanking you, Yours sincerely, For Zensar Technologies Limited Anand Daga Company Secretary Encl.: As above CIN: L72200PN1963PLC012621 www.zensar.com Zensar Technologies Limited, Zensar +(20) 6607 4000, 2700 4000 investor@zensar.com Knowledge Park, Plot No. 4, MIDC Kharadi, Off Nagar Road, Pune 411014 Annexure – I Details pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the SEBI Master Circular dated January 30, 2026 S. Particulars Disclosure 1. Name of the entity(ies) forming Below are brief details (on standalone basis) as on and for part of the merger, details in the year ended March 31, 2026: brief such as size, turnover, etc. (In USD Million) Entity Name N et worth Turnover Bridgeview Life Sciences 0.4 4.74 M3BI LLC 9.32 46.8 Zensar Technologies Inc. 74.66 326.96 2. Whether the transaction would No fall within related party transactions? If yes, whether the As per Regulation 23(5)(b) of the SEBI (Listing Obligations same is done at “arm’s length” and Disclosure Requirements) Regulations, 2015, the related party transaction provisions are not applicable to the proposed merger. 3. Area of business of the entity(ies) Entity Area of Business Bridgeview Life Sciences The entities are engaged in LLC providing digital solutions M3BI LLC and technology services to Zensar Technologies Inc. global organizations. 4. Rationale for merger To achieve greater business synergies and higher operational efficiencies. It will also lead to effective management and unified control of operations. 5. In case of cash consideration - Not applicable - the proposed merger is between step- amount or otherwise share down subsidiary(ies) of Zensar Technologies Limited. exchange ratio 6. Brief details of change in There shall be no change in the shareholding pattern of shareholding pattern (if any) of Zensar Technologies Limited. the listed entity CIN: L72200PN1963PLC012621 www.zensar.com Zensar Technologies Limited, Zensar + (20) 6607 4000, 2700 4000 investor@zensar.com Knowledge Park, Plot No. 4, MIDC Kharadi, Off Nagar Road, Pune 411014